# Definium Therapeutics, Inc.: filings

DFTX · Nasdaq · CIK 1813814 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/dftx.md) · [Financials](/companies/dftx/financials.md) · [Filings](/companies/dftx/filings.md) · [Insiders](/companies/dftx/insiders.md)

## Reports and events: 150 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 160, 8-K 78, 144 48, 6-K 46, DEFA14A 30, 3 18, DFAN14A 17, 10-Q 14, 424B5 9, 4/A 8, SCHEDULE 13G/A 7, D 6, 10-K 5, S-8 5, DEF 14A 4, SC 13G 4, UPLOAD 4, 424B3 3, 8-K/A 3, ARS 3, CORRESP 3, EFFECT 3, DEFC14A 2, PREC14A 2, S-3 2, SC 13G/A 2, SCHEDULE 13G 2, 424B7 1, 8-A12B 1, CERT 1, F-10 1, F-10/A 1, F-X 1, PRE 14A 1, PRER14A 1, PRRN14A 1, S-3ASR 1, S-3MEF 1, S-8 POS 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-14 | 08:02 ET | [8-K](/filings/0001104659-26-107275.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-107275 |
| 2026-09-08 | 08:00 ET | [8-K](/filings/0001193125-26-384403.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-384403 |
| 2026-08-12 | 08:05 ET | [8-K](/filings/0001104659-26-094528.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-094528 |
| 2026-08-06 | 16:16 ET | [10-Q](/filings/0001193125-26-338066.md) | Quarterly report, period 2026-06-30 | 0001193125-26-338066 |
| 2026-08-06 | 16:10 ET | [8-K](/filings/0001193125-26-338006.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-338006 |
| 2026-06-24 | 17:14 ET | [8-K](/filings/0001104659-26-077354.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-077354 |
| 2026-06-22 | 08:01 ET | [8-K](/filings/0001104659-26-076091.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-076091 |
| 2026-06-12 | 16:30 ET | [8-K](/filings/0001193125-26-269549.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-269549 |
| 2026-05-19 | 07:30 ET | [8-K](/filings/0001193125-26-229657.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-229657 |
| 2026-05-12 | 08:15 ET | [8-K](/filings/0001193125-26-218251.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-218251 |
| 2026-05-07 | 16:17 ET | [10-Q](/filings/0001193125-26-211989.md) | Quarterly report, period 2026-03-31 | 0001193125-26-211989 |
| 2026-05-07 | 16:12 ET | [8-K](/filings/0001193125-26-211929.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-211929 |
| 2026-04-27 | 16:05 ET | [DEF 14A](/filings/0001193125-26-182034.md) | Proxy statement, period 2026-06-11 | 0001193125-26-182034 |
| 2026-04-22 | 16:22 ET | [8-K](/filings/0001193125-26-170509.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-170509 |
| 2026-02-26 | 16:16 ET | [10-K](/filings/0001193125-26-076742.md) | Annual report, period 2025-12-31 | 0001193125-26-076742 |
| 2026-02-26 | 16:10 ET | [8-K](/filings/0001193125-26-076612.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-076612 |
| 2026-01-29 | 07:30 ET | [8-K](/filings/0001193125-26-028186.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-028186 |
| 2026-01-12 | 08:24 ET | [8-K](/filings/0001193125-26-009854.md) | 2.02 Results of operations; 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-009854 |
| 2025-11-06 | 16:18 ET | [10-Q](/filings/0001193125-25-269596.md) | Quarterly report, period 2025-09-30 | 0001193125-25-269596 |
| 2025-11-06 | 16:12 ET | [8-K](/filings/0001193125-25-269548.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-269548 |
| 2025-10-31 | 09:22 ET | [8-K](/filings/0001104659-25-104696.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-104696 |
| 2025-10-29 | 16:11 ET | [8-K](/filings/0001104659-25-103726.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-103726 |
| 2025-09-04 | 11:15 ET | [8-K](/filings/0000950170-25-112973.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-112973 |
| 2025-07-31 | 16:20 ET | [10-Q](/filings/0000950170-25-100925.md) | Quarterly report, period 2025-06-30 | 0000950170-25-100925 |
| 2025-07-31 | 16:10 ET | [8-K](/filings/0000950170-25-100902.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-100902 |
| 2025-06-16 | 17:00 ET | [8-K](/filings/0000950170-25-086830.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950170-25-086830 |
| 2025-05-27 | 07:30 ET | [8-K](/filings/0001104659-25-052719.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-25-052719 |
| 2025-05-08 | 07:25 ET | [10-Q](/filings/0000950170-25-066387.md) | Quarterly report, period 2025-03-31 | 0000950170-25-066387 |
| 2025-05-08 | 07:15 ET | [8-K](/filings/0000950170-25-066374.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-066374 |
| 2025-04-23 | 16:15 ET | [DEF 14A](/filings/0001104659-25-038010.md) | Proxy statement, period 2025-06-12 | 0001104659-25-038010 |
| 2025-04-21 | 16:15 ET | [8-K](/filings/0001104659-25-036841.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001104659-25-036841 |
| 2025-04-15 | 07:45 ET | [8-K](/filings/0000950170-25-053953.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-053953 |
| 2025-03-06 | 07:40 ET | [10-K](/filings/0000950170-25-034176.md) | Annual report, period 2024-12-31 | 0000950170-25-034176 |
| 2025-03-06 | 07:30 ET | [8-K](/filings/0000950170-25-034175.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-034175 |
| 2025-01-30 | 07:45 ET | [8-K](/filings/0000950170-25-010802.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-010802 |
| 2025-01-13 | 08:00 ET | [8-K](/filings/0001104659-25-002868.md) | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-002868 |
| 2024-12-16 | 07:30 ET | [8-K](/filings/0000950170-24-136386.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-136386 |
| 2024-11-07 | 16:25 ET | [10-Q](/filings/0000950170-24-123391.md) | Quarterly report, period 2024-09-30 | 0000950170-24-123391 |
| 2024-11-07 | 16:15 ET | [8-K](/filings/0000950170-24-123366.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-123366 |
| 2024-10-17 | 16:18 ET | [8-K](/filings/0001104659-24-109539.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-109539 |
| 2024-08-13 | 07:25 ET | [10-Q](/filings/0000950170-24-095753.md) | Quarterly report, period 2024-06-30 | 0000950170-24-095753 |
| 2024-08-13 | 07:15 ET | [8-K](/filings/0000950170-24-095749.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-095749 |
| 2024-08-12 | 08:38 ET | [8-K](/filings/0001104659-24-088108.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-088108 |
| 2024-06-28 | 08:20 ET | [8-K](/filings/0001104659-24-076037.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-076037 |
| 2024-06-20 | 08:00 ET | [8-K](/filings/0000950170-24-075317.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-075317 |
| 2024-06-11 | 16:30 ET | [8-K](/filings/0000950170-24-071953.md) | 5.07 Shareholder vote results | 0000950170-24-071953 |
| 2024-05-08 | 16:15 ET | [10-Q](/filings/0000950170-24-055681.md) | Quarterly report, period 2024-03-31 | 0000950170-24-055681 |
| 2024-05-08 | 16:10 ET | [8-K](/filings/0000950170-24-055649.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-055649 |
| 2024-04-26 | 08:00 ET | [DEF 14A](/filings/0001104659-24-052454.md) | Proxy statement, period 2024-06-10 | 0001104659-24-052454 |
| 2024-04-01 | 17:03 ET | [8-K](/filings/0000950170-24-039484.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-039484 |

Page 1 of 3. [Older](/companies/dftx/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:06 ET. No prices; not investment advice.